Cargando…

Propranolol eye drops in patients with corneal neovascularization

RATIONALE: Studies performed in animal models of corneal neovascularization suggested the possible efficacy of a treatment with propranolol. Corneal neovascularization is one of the most feared complications of Stevens–Johnson syndrome that frequently involves ocular surface. We report the first 2 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Filippi, Luca, de Libero, Cinzia, Zamma Gallarati, Barbara, Fortunato, Pina, Piozzi, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250516/
https://www.ncbi.nlm.nih.gov/pubmed/30407290
http://dx.doi.org/10.1097/MD.0000000000013002
_version_ 1783372929814233088
author Filippi, Luca
de Libero, Cinzia
Zamma Gallarati, Barbara
Fortunato, Pina
Piozzi, Elena
author_facet Filippi, Luca
de Libero, Cinzia
Zamma Gallarati, Barbara
Fortunato, Pina
Piozzi, Elena
author_sort Filippi, Luca
collection PubMed
description RATIONALE: Studies performed in animal models of corneal neovascularization suggested the possible efficacy of a treatment with propranolol. Corneal neovascularization is one of the most feared complications of Stevens–Johnson syndrome that frequently involves ocular surface. We report the first 2 patients with severe ocular neo-vascularization treated with different degrees of success, with propranolol eye drops. PATIENT CONCERNS: Two patients with corneal neovascularization complicating the Stevens–Johnson syndrome, not responsive to steroids and cyclosporine, were treated with propranolol eye drops. DIAGNOSES: Corneal neovascularization was detected by ophthalmoscopic evaluation. INTERVENTIONS: Topical treatment with propranolol eye drops at different concentrations. OUTCOMES: Both patients reported dramatic subjective benefits (reduction of photophobia and discomfort) without adverse effects, and in the patient with a less advanced disease, an objective reduction of neovascularization and an improved visual acuity was observed. LESSONS: This experience suggests that propranolol might be an inexpensive, safe and effective treatment in counteracting the progression of corneal neovascularization.
format Online
Article
Text
id pubmed-6250516
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-62505162018-12-10 Propranolol eye drops in patients with corneal neovascularization Filippi, Luca de Libero, Cinzia Zamma Gallarati, Barbara Fortunato, Pina Piozzi, Elena Medicine (Baltimore) Research Article RATIONALE: Studies performed in animal models of corneal neovascularization suggested the possible efficacy of a treatment with propranolol. Corneal neovascularization is one of the most feared complications of Stevens–Johnson syndrome that frequently involves ocular surface. We report the first 2 patients with severe ocular neo-vascularization treated with different degrees of success, with propranolol eye drops. PATIENT CONCERNS: Two patients with corneal neovascularization complicating the Stevens–Johnson syndrome, not responsive to steroids and cyclosporine, were treated with propranolol eye drops. DIAGNOSES: Corneal neovascularization was detected by ophthalmoscopic evaluation. INTERVENTIONS: Topical treatment with propranolol eye drops at different concentrations. OUTCOMES: Both patients reported dramatic subjective benefits (reduction of photophobia and discomfort) without adverse effects, and in the patient with a less advanced disease, an objective reduction of neovascularization and an improved visual acuity was observed. LESSONS: This experience suggests that propranolol might be an inexpensive, safe and effective treatment in counteracting the progression of corneal neovascularization. Wolters Kluwer Health 2018-11-09 /pmc/articles/PMC6250516/ /pubmed/30407290 http://dx.doi.org/10.1097/MD.0000000000013002 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle Research Article
Filippi, Luca
de Libero, Cinzia
Zamma Gallarati, Barbara
Fortunato, Pina
Piozzi, Elena
Propranolol eye drops in patients with corneal neovascularization
title Propranolol eye drops in patients with corneal neovascularization
title_full Propranolol eye drops in patients with corneal neovascularization
title_fullStr Propranolol eye drops in patients with corneal neovascularization
title_full_unstemmed Propranolol eye drops in patients with corneal neovascularization
title_short Propranolol eye drops in patients with corneal neovascularization
title_sort propranolol eye drops in patients with corneal neovascularization
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250516/
https://www.ncbi.nlm.nih.gov/pubmed/30407290
http://dx.doi.org/10.1097/MD.0000000000013002
work_keys_str_mv AT filippiluca propranololeyedropsinpatientswithcornealneovascularization
AT deliberocinzia propranololeyedropsinpatientswithcornealneovascularization
AT zammagallaratibarbara propranololeyedropsinpatientswithcornealneovascularization
AT fortunatopina propranololeyedropsinpatientswithcornealneovascularization
AT piozzielena propranololeyedropsinpatientswithcornealneovascularization